Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$8.30
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.30
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.74M
Market Cap
$969.20M
Enterprise Value$1.04B
Total Cash (Recent Filing)$200.97M
Total Debt (Recent Filing)$96.52M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding99,303,260
10 Day Avg. Volume1,372,409
30 Day Avg. Volume1,741,730
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue10.46
Enterprise Value/Gross Profit13.57
Enterprise Value/Ebitda-5.39
Forecast
1Y Price Target
$28.33Price Target Upside241.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.58
Revenue Forecast (FY)$149.35M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginSustained top-line growth with a ~75.8% gross margin indicates attractive product economics and improving demand for neffy. Durable unit economics support scalability as volumes grow, enabling margin expansion potential as fixed commercial costs are spread over higher revenue.
Regulatory And Market ExpansionRegulatory approvals (broadened FDA label, Health Canada, EU marketing authorization) materially expand the addressable market and enable international partner commercialization. These approvals create durable growth avenues beyond the U.S. franchise and support longer-term revenue diversification.
Cash Runway And Path To BreakevenA $201M cash balance paired with a stated plan to reach cash‑flow breakeven by mid‑2027 gives the company runway to execute commercialization and payer strategies. Adequate near-term liquidity reduces immediate financing risk while plans to scale refills and coverage support durability.
Bears Say
Negative Operating Cash Flow / Cash BurnPersistent, large negative operating cash flow (~-$175M TTM) reflects heavy burn from commercialization and limits optionality. If revenue cadence or payer wins lag, the company may need external financing, which can dilute shareholders and constrain long-term strategy execution.
High SG&A From Commercialization InvestmentsElevated SG&A to build field force and DTC programs creates structural cost pressure relative to current revenue. Until refills and payer access scale, sustained high selling expenses will compress operating leverage and delay durable profitability despite strong unit economics.
Payor Access Friction & Prescription AbandonmentSignificant prior‑authorization barriers (43% of covered lives) and ~22–23% abandonment materially reduce realized demand and create structural friction. Durable growth depends on sustained payer wins and lower abandonment; failure to convert coverage into fills constrains long‑term revenue conversion.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $969.20M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 56 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on May 15, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.516 by -$0.094.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,303,260 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.516. Following the earnings report the stock price went down -6.486%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.33 (241.37% Upside)
$28.33 (241.37% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 339.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.25%
12-Months-Change
Fundamentals
Return on Equity
-153.61%
Trailing 12-Months
Asset Growth
-12.14%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
SPRY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress (robust YoY prescription and revenue growth, regulatory approvals, expanded coverage and new affordability programs), backed by a healthy cash balance and a clear plan to scale through the back-to-school season and refill cycles. However, execution risks remain: significant SG&A spend and cash burn, prior-authorization friction that still limits access for a meaningful portion of covered lives, notable prescription abandonment, and uncertainty around timing of key payer decisions (e.g., CVS Caremark). On balance, the positives around growth, access expansion, regulatory wins and commercial initiatives outweigh the operational challenges, but the company remains execution- and timing-dependent over the coming quarters.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$28.33
▲(241.37% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
59.91% Insiders
8.29% Mutual Funds
11.65% Other Institutional Investors
10.87% Public Companies and
Individual Investors